Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Unpopulated and in the middle of nowhere, Point Nemo is starting to have a history. This article appears in the November 2024 ...

BOSTON--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

At the intersection of biology and AI, Somite.ai is pioneering the future of repairing human bodies by applying the predictive power of engineering.

CEO Sundar Pichai confirmed during an earnings call that much of the company's code is AI-generated and human-reviewed.

GitHub CoPilot expands to multiple models, from OpenAI to Google; Google Vertex AI protects private data while pushing ...

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Through a multiyear agreement, Citigroup is cloudifying the way it delivers software to employees, customers and its markets ...

We are very pleased with the broadening of our innovative pipeline in renal medicine which now spans programs in AMKD, IgAN, pMN and polycystic kidney disease,” said Carmen Bozic, M.D., Executive Vice ...